These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Progress in the pharmacotherapy of uveitis: the art of personalized care. Patel SH; Belamkar A; Hajrasouliha AR; Jusufbegovic D; Ciulla TA Expert Opin Pharmacother; 2022 Aug; 23(12):1445-1455. PubMed ID: 35880543 [TBL] [Abstract][Full Text] [Related]
9. Definition of Uveitis Refractory to Treatment: A Systematic Review in the Absence of a Consensus. Valenzuela RA; Flores I; Pujol M; Llanos C; Carreño E; Rada G; Herbort CP; Cuitino L; Urzua CA Ocul Immunol Inflamm; 2022 Jan; 30(1):174-179. PubMed ID: 32886537 [TBL] [Abstract][Full Text] [Related]
10. Controlled release of corticosteroid with biodegradable nanoparticles for treating experimental autoimmune uveitis. Luo L; Yang J; Oh Y; Hartsock MJ; Xia S; Kim YC; Ding Z; Meng T; Eberhart CG; Ensign LM; Thorne JE; Stark WJ; Duh EJ; Xu Q; Hanes J J Control Release; 2019 Feb; 296():68-80. PubMed ID: 30660629 [TBL] [Abstract][Full Text] [Related]
11. A comprehensive review and update on the biologic treatment of adult noninfectious uveitis: part II. Lee K; Bajwa A; Freitas-Neto CA; Metzinger JL; Wentworth BA; Foster CS Expert Opin Biol Ther; 2014 Nov; 14(11):1651-66. PubMed ID: 25226284 [TBL] [Abstract][Full Text] [Related]
12. Safety of systemic therapy for noninfectious uveitis. Ormaechea MS; Hassan M; Onghanseng N; Park JH; Mahajan S; Al-Kirwi KY; Uludag G; Halim MS; Schlaen A; Sepah YJ; Do DV; Nguyen QD Expert Opin Drug Saf; 2019 Dec; 18(12):1219-1235. PubMed ID: 31801415 [No Abstract] [Full Text] [Related]
13. Side-effects of anti-inflammatory therapy in uveitis. Uchiyama E; Papaliodis GN; Lobo AM; Sobrin L Semin Ophthalmol; 2014; 29(5-6):456-67. PubMed ID: 25325874 [TBL] [Abstract][Full Text] [Related]
15. The Ocular Immunology and Uveitis Foundation preferred practice patterns of uveitis management. Foster CS; Kothari S; Anesi SD; Vitale AT; Chu D; Metzinger JL; Cerón O Surv Ophthalmol; 2016; 61(1):1-17. PubMed ID: 26164736 [TBL] [Abstract][Full Text] [Related]
16. The Conundrum of Clinical Trials for the Uveitides: Appropriate Outcome Measures for One Treatment Used in Several Diseases. Jabs DA; Berkenstock MK; Altaweel MM; Holbrook JT; Sugar EA; Epidemiol Rev; 2022 Dec; 44(1):2-16. PubMed ID: 35442407 [TBL] [Abstract][Full Text] [Related]
17. New pharmacotherapy options for noninfectious posterior uveitis. Pleyer U; Stübiger N Expert Opin Biol Ther; 2014 Dec; 14(12):1783-99. PubMed ID: 25243865 [TBL] [Abstract][Full Text] [Related]
18. Road to remission: a comprehensive review of therapy in uveitis. Siddique SS; Shah R; Suelves AM; Foster CS Expert Opin Investig Drugs; 2011 Nov; 20(11):1497-515. PubMed ID: 21936708 [TBL] [Abstract][Full Text] [Related]
19. [Treatment of posterior noninfectious uveitis : Current situation and future developments]. Pleyer U; Pohlmann D; Stübiger N Ophthalmologe; 2016 May; 113(5):380-90. PubMed ID: 27165275 [TBL] [Abstract][Full Text] [Related]
20. Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. Nguyen QD; Merrill PT; Jaffe GJ; Dick AD; Kurup SK; Sheppard J; Schlaen A; Pavesio C; Cimino L; Van Calster J; Camez AA; Kwatra NV; Song AP; Kron M; Tari S; Brézin AP Lancet; 2016 Sep; 388(10050):1183-92. PubMed ID: 27542302 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]